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Abstract 
Diabetes is a common endocrine disorder with an ever increasing prevalence globally, 
placing significant burdens on our healthcare systems. It is associated with significant 
cardiovascular morbidities. One of the mechanisms by which it causes death is increasing the 
risk of cardiac arrhythmias. The aim of this article is to review the cardiac (ion channel 
abnormalities, electrophysiological and structural remodelling) and extra-cardiac factors 
(neural pathway remodelling) responsible for cardiac arrhythmogenesis in diabetes.  It is 
concluded by an outline of molecular targets for future anti-arrhythmic therapy for the 
diabetic population. 
 
 Introduction 
Cardio-metabolic disorders place significant burdens on the healthcare system 
worldwide. Their prevalence has been rising over the past decades due to an aging population 
and an increasing level of obesity [1, 2]. Diabetes mellitus is an endocrine disorder 
characterized by reduced insulin production (type 1) or increased insulin resistance (type 2), 
leading to hyperglycaemia. There is increasing evidence that diabetes increases the risk of 
cardiac arrhythmias. This involves abnormalities in action potential conduction or 
repolarization (Figures 1 and 2), due to a complex interplay of ion channel abnormalities and 
electrophysiological remodelling superimposed upon a cardiomyopathic process together 
with autonomic dysregulation (Figure 3). Some of these findings are derived from 
experiments performed in animal models, which have been proven extremely useful for 
dissecting the molecular mechanisms responsible for arrhythmic phenotypes [3]. In this 
review, the pathophysiology underlying cardiac arrhythmias in diabetes mellitus are explored 
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in detail, followed by an outline of potential therapeutic targets for reducing arrhythmic risk 
and sudden death in diabetic patients. 
 
Arrhythmogenic mechanisms in diabetes mellitus 
The common arrhythmogenic mechanism is re-entry, which occurs when an action 
potential fails to extinguish itself and re-activates a region that has recovered from 
refractoriness. This can arise from abnormalities in conduction or repolarization, or both [4, 
5]. Circus re-entry requires three prerequisites: i) conduction velocity (CV) must be 
sufficiently slowed so that the tissue ahead of the action potential (AP) wavefront remains 
excitable, ii) unidirectional conduction block must be present to prevent waves from self-
extinguishing when they collide, and iii) an obstacle around which an AP can circulate [6]. 
This need not to be a structural defect, but can be a functional core of refractory tissue, which 
may arise dynamically from ectopic activity [7]. Repolarization abnormalities can result in 
early or delayed afterdepolarizations (EADs and DADs), which can initiate triggered activity 
when their magnitudes are sufficiently large to reach the threshold potential for sodium 
channel reactivation. They can also increase the dispersion of repolarization, promoting 
unidirectional conduction block and reentry. In diabetes mellitus, arrhythmogenesis can be 
due to the following mechanisms. Abnormalities in conduction are mediated by myocardial 
ischaemia [8], or in repolarization [9, 10] by ion channel dysfunction, increased adrenergic 
drive and calcium overload. These abnormalities are superimposed upon a cardiomyopathy, 
in which the structural changes also predispose to arrhythmias. Extra-cardiac abnormalities, 
for example neural pathway remodelling, can further promote arrhythmogenesis [11]. 
Ventricular arrhythmias are thought to underlie sudden cardiac death (SCD) in type 2 diabetic 
patients, and also the “dead-in-bed syndrome” observed in otherwise young healthy adults 
with type 1 diabetes [12]. 
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Abnormal conduction 
CV depends upon sodium channel activation followed by electrotonic spread of the 
ionic currents via gap junctions, which are electrical coupling pathways located between 
adjacent cardiomyocytes [4].  Each gap junction is made of two connexons, and each 
connexon is a hexamer of connexins (Cx). Altered gap junction expression or function can 
produce conduction abnormalities and in turn predisposing to reentrant excitation [13, 14]. 
Protein Kinase C (PKC)-mediated phosphorylation, a calcium-dependent process, at serine 
368 of Cx43, has been linked to reduced gap junction conductance [15, 16]. 
Dephosphorylation of gap junctions results in their uncoupling [17] and lateralization [18, 
19]. There is consistent evidence demonstrating that altered gap junction function or 
expression in different experimental models of diabetes. Thus, in transgenic mice with 
cardiac-specific overexpression of peroxisome proliferator-activated receptor γ 1 (PPARγ1) 
modelling human diabetes, reduced Cx43 expression without alterations in CV was observed 
[20]. This may increase anisotropy and higher likelihood of reentry. In streptozotocin (STZ)-
induced diabetic rats, expression levels of Cx40, 43 and 45 in the SA node are significantly 
increased, which were associated with SA conduction delay [21]. This can be explained by 
increased expression levels of Cx45, which has the lowest unitary conductance and whose 
expression reduces CV. In both atria and ventricles of the same model, Cx43 phosphorylation 
was decreased because of reduced PKCε expression [22]; Cx43 was upregulated in the atria, 
whereas its expression level was unchanged in the ventricles [23]. Furthermore, the lack of 
insulin signaling can lead to reduced CV of propagating APs,  
Myocardial fibrosis is increasingly recognized to be a pathogenic factor in diabetic 
cardiomyopathy [24]. Fibrosis resulting from fibroblast activation is mediated by growth 
factors, such as transforming growth factor-β [25]. This produces conduction abnormalities 
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via two mechanisms: i) reduced coupling between cardiomyocytes, leading to increased axial 
resistance; ii) increased coupling between fibroblast and cardiomyocyte, increasing 
membrane capacitance [26]. Both mechanisms lead to a decrease in CV. Cardiac magnetic 
resonance (CMR) with late gadolinium enhancement is used for the diagnosis and monitoring 
of cardiomyopathy [27-29] and is potentially useful for examining fibrosis in diabetic 
cardiomyopathy. 
Hypoglycemic episodes are associated with myocardial ischaemia [8], which may 
predispose to ventricular arrhythmias by producing conduction defects via the following 
mechanisms [4]. Ischaemia results in ATP depletion, metabolic switching to anaerobic 
glycolysis, extracellular H
+
 accumulation and intracellular Ca
2+
 overload. Cytosolic Ca
2+
 
binds to the conserved C2 domain of PKC, thereby activating it [30]. There are several 
downstream targets of PKC. Firstly, PKC phosphorylates the serine residue at 1505 position 
of the sodium channel inactivation gate between domains III and IV, which decreases INa 
[31]. Secondly, it also phosphorylates connexins (Cx) 43 at serine 368, reducing gap junction 
conductance [15, 16]. Ca
2+
 overload is also associated with dephosphorylation of gap 
junctions [32], resulting in their uncoupling [17] and lateralization [18, 19]. Thus, myocardial 
ischemia secondary to hypoglycemia reduces CV and increases dispersion of conduction, 
predisposing to reentrant excitation.  
 
Abnormal repolarization 
Action potential repolarization has two phases: i) early rapid repolarization resulting 
from the activation of the fast and slow transient outward potassium currents, Ito,f and Ito,s, and 
ii) prolonged plateau resulting from a balance between the inward currents mediated by the 
voltage-gated L-type calcium channel (LTCC, ICa,L) and sodium-calcium exchanger  (INCX), 
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and the outward currents mediated by the voltage-gated delayed rectifier potassium channels 
(IK: rapid and slow currents, IKr and IKs) [33]. There is also contribution from the inward 
rectifying current (IK1). Of these, the human ether-à-go-go-related gene (HERG) K
+
 channel 
is the major component of delayed rectifier K
+
 current [34].  
In diabetes mellitus, prolongations in action potential durations (APDs) are due to 
several mechanisms. The lack of insulin signaling resulted in electrophysiological 
remodelling: Ito is reduced as a result of reduced expression of Kv4.2 and KChiP2 genes [35]. 
This current is post-translationally regulated by a number of different kinases. For example, 
the p90 ribosomal S6 kinase (p90RSK) is a serine/threonine kinase with N- and C-terminal 
kinase domains. Reactive oxygen species (ROS), which are raised in diabetes, increases the 
activity of p90RSK and reduced the activity of Ito, f, IK, slow and ISS channels [36]. Moreover, 
transgenic mice with cardiac-specific overexpression of peroxisome proliferator-activated 
receptor γ 1 (PPARγ1) showed abnormal lipid accumulation in cardiomyocytes and reduced 
expression as well as function of Ito, f and IK, slow [20]. The Rad (Ras associated with diabetes) 
protein is implicated in diabetes: in its dominant negative mutant, LTCC was upregulated 
[37]. Together, increased inward currents and decreased outward currents lead to prolonged 
ventricular repolarization. Conversely, genetic mutations of key ion channel genes causing 
prolonged ventricular repolarization can also lead to diabetes. For example, mutations in 
KCNE2 are responsible for long QT syndrome type 5. Whole-transcript transcriptomics 
demonstrated that KCNE2
-/-
 mice additionally showed diabetes mellitus, 
hypercholesterolemia and elevated angiotensin II levels [38]. Hypoglycemia causes 
intracellular depletion of ATP in cardiomyocytes and hyperglycemia increases the production 
of reactive oxygen species (ROS), both leading to HERG channel dysfunction [39]. KATP 
channels are thought to provide a link between cellular energy status and membrane 
electrophysiology. They are normally inhibited by ATP and activated by ADP. During 
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ischemia, there are ATP depletion and ADP accumulation, activating IK, ATP and promoting 
APD shortening [40]. In diabetes, initial APD shortening is also observed but this becomes 
fully reversed in a time-dependent manner. This failure of APD adaptation, when 
accompanied by increased adrenergic drive, can engage in steep APD restitution, in turn 
leading to the production of arrhythmogenic APD alternans [7]. 
Hypoglycemia is also associated with another cause of delayed repolarization, 
hypokalaemia [41, 42], which arises from insulin therapy or increased adrenergic drive [43, 
44]. Hypokalaemia inhibits IK1, thereby prolonging APDs and causing L-type Ca
2+
 channel 
reactivation [45]. This then leads to early afterdepolarizations (EADs) and consequent 
triggered activity [14]. Hypokalaemia also preferentially prolongs epicardial APDs and 
leaving endocardial APDs unchanged, increasing the transmural repolarization gradient [14]. 
In combination with reduced effective refractory periods (ERPs), excitation wavelength 
(conduction velocity (CV) x ERP) is reduced [6]. Furthermore, increased steepness of APD 
restitution results in the development of APD alternans [46] and in turn to wavebreak, 
conduction block, initiation and maintenance of reentrant activity [7, 47].  
Hypoglycemia also increases adrenergic drive with the following pro-arrhythmic 
consequences [48]. Firstly, the release of catecholamines leads to abnormal Ca
2+
 cycling and 
intracellular Ca
2+
 accumulation. This in turn stimulates spontaneous Ca
2+
 release from the 
sarcoplasmic reticulum, thereby activating three calcium-sensitive currents: the nonselective 
cationic current, INS, the sodium-calcium exchange current, INCX, and the calcium-activated 
chloride current, ICl, Ca. Thus, such inward currents observed during phase 4 of the action 
potential lead to delayed afterdepolarizations (DADs), eliciting triggered activity.  
Abnormal Ca
2+
 dynamics have been implicated in diabetes. For example, 
cardiomyocytes of leptin-deficient ob/ob mice showed reduced amplitudes of Ca
2+
 transients, 
and insulin elicited extra transients via inositol 1,4,5-trisphosphate (IP3) signaling and 
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impaired mitochondrial Ca
2+
 handling [49]. Furthermore, decreases in DAG-mediated non-
selective cation currents were associated with reduced TRPC3 expression at the plasma 
membrane, which increases Ca
2+
 influx [50]. Dysregulation of the type 2 ryanodine receptor 
(RyR2) has been detected in a STZ-induced diabetes rat model, in which increased frequency 
of Ca
2+
 sparks with reduced amplitudes were associated with increased sensitivity to Ca
2+
 
activation and dyssynchronous Ca
2+
 release [51, 52]. Abnormal RyR2 gating mechanism may 
arise from increased phosphorylation by protein kinase A (PKA, serine 2808) and 
Ca
2+
/calmodulin-dependent protein kinase II (CaMKII, serine 2808 and 2814) [53-55], as 
well as oxidation by ROS and reactive carbonyl species (RCS), which are increased in 
diabetes [56-58]. Uncontrolled hyperglycaemia can lead to activation of CaMKII and 
subsequent Ca
2+
 release from the SR [59]. Dyssynchronous Ca
2+
 release can be explained by 
remodelling of the transverse tubular system, whereby RyR2 become orphaned when they are 
decoupled from LTCCs [60]. Interestingly, catecholaminergic polymorphic ventricular 
tachycardia (CPVT) is caused by RyR2 mutation, and patients suffering from this condition 
are also prone to impaired glucose homeostasis and insulin secretion [61]. It would be 
interesting to determine whether diabetic patients with acquired dysfunction in RyR2, 
develop bidirectional VT classically associated with CPVT. 
 Moreover, diabetes mellitus is an independent risk factor for atrial fibrillation, yet the 
underlying physiological mechanisms are incompletely understood. It may involve ion 
channel remodelling in the atria. For example, the small conductance Ca
2+
-activated K
+
 (SK) 
channels contribute to atrial repolarization. SK2 and SK3 isoforms are downregulated, 
leading to APD prolongation [62]. Normally, SK channels do not play a role in ventricular 
repolarization. In heart failure, SK currents and ion channel expression can be upregulated, 
and become more sensitive to Ca
2+
 modulation, potentially leading to ventricular arrhythmias 
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[63]. Altered expression of SK channels in the ventricles may play a role in diabetes but this 
remains to be tested experimentally. 
 
Diabetic cardiomyopathy: cardiac electrophysiological and structural remodelling with 
superimposed autonomic dysregulation 
Diabetic cardiomyopathy is characterized by diastolic dysfunction with preserved 
systolic function, findings that are similarly observed in genetically modified, leptin receptor 
deficient, diabetic db/db mice on echocardiography [64]. [65]. Cardiac magnetic resonance 
imaging is excellent for characterizing structural abnormalities, such as areas of fibrosis by 
late gadolinium enhancement [27-29]. Afferent and efferent neural pathways normally 
regulate inotropic, lusitropic, chronotropic and dromotropic responses of the heart. In 
diabetes, these can become dysregulated with impaired baroreceptor control of heart rate 
[66]. Reduced heart rate variability (HRV) has long been associated with increased mortality 
[67]. In diabetes, a reduction in HRV was associated with increased incidence of inducible 
VT by programmed electrical stimulation [68]. Electrophysiological modelling is likely to be 
an early event, appearing before structural abnormalities. Thus, STZ-induced diabetic rats 
showed decreases in both maximal transport capacity of SERCA2a and RyR2 conductance, 
associated with impairment of both inotropic and lusitropic responses in response to 
adrenergic stimulation [69]. This finding differs from human findings where impaired 
positive inotropic response with preservation of positive lusiotropic effects of beta-
adrenoceptor stimulation [70].  
Brady-arrhythmias in the form of sinoatrial (SA) and atrioventricular (AV) nodal 
blocks are seen in diabetes [71, 72]. Sinoatrial node (SAN) dysfunction was demonstrated in 
db/db mice, which demonstrated prolonged SAN recovery time [64]. These mice showed no 
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significant differences in conduction intervals and wave amplitudes compared to control 
mice. By contrast, sinus tachycardia at rest has been associated with excessive mortality in 
diabetic patients [73]. This may be related to autonomic dysregulation, with increased 
adrenergic drive with or without impairment of parasympathetic response. Thus, in Akita 
diabetic mice, reduced response of the SA node to acetylcholine due to decreased 
acetylcholine-activated K
+
 current (IK, ACh), attributable to altered phosphoinositide 3-kinase 
(PI3K) signaling [74].  
Some aspects of altered cardiac electrophysiology in diabetes do not arise from 
abnormalities in the heart itself, but instead from neural pathways innervating it. Thus, in 
STZ-induced diabetic mice, both baroreflex tachycardia and bradycardia were blunted. This 
was associated with remodelling of the baroreceptor circuitry, in which the sizes of cardiac 
ganglia and ganglionic principal neurons were decreased. In a different model, the OVE26 
diabetic mice showed neural degeneration in the nucleus ambiguus, which is one of the two 
brainstem nuclei innervating the cardiac ganglia [75]. Furthermore, altered balance between 
chemoattractants (e.g. nerve growth factor) and chemorepellants (Sema3a) leads to 
disruptions in innervation pattern, precipitating arrhythmias and sudden death [76]. 
 
Clinical Relevance and future therapies 
Traditional agents used for treatment of diabetes or associated comorbidities such as 
hypertension have been shown to exert cardiac protective effects in diabetes by previously 
unknown mechanisms. Thus, for example in the STZ-induced diabetic rat model, Ito and Iss 
are downregulated and the cardiac renin-angiotensin system is activated. Experimental 
evidence has demonstrated augmentation of both currents by the antihypertensive angiotensin 
II receptor blockers [77]. The ACE inhibitor enalapril [78], the angiotensin II receptor 
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blocker losartan [79] was also shown to exert anti-fibrotic effects in hypertension and may 
could similar cardioprotective effects in diabetes by similar mechanisms. The anti-fibrotic 
hormone relaxin could be delivered using adenoviruses [80] and may reverse fibrosis in 
diabetic cardiomyopathy. Ion channels represent an attractive target for managing arrhythmic 
complications of diabetes mellitus (Table 1). Novel agents such as late sodium current 
blockers [81] and gap junction openers [82] can be used to reduce abnormal repolarization 
and conduction, respectively. Alternatively, gap junction inhibitors can prolong effective 
refractory periods and exert anti-arrhythmic effects [14, 83]. Paradoxically, mild gap junction 
uncoupling could improve the safety margin of conduction and increase CV, removing 
unidirectional conduction blocks and converting these into bilateral conduction. Their use in 
diabetes warrant future exploration. Ryanodine receptor stabilizers have the potential to 
normalize Ca
2+
 handling in diabetes, which remains to be tested [84]. However, caution must 
be taken to screen for deleterious, ventricular pro-arrhythmic effects. KATP channels play a 
role in not only insulin secretion but also cardiac repolarization. Whilst the KATP channel 
activators have been used to increase insulin release, they have the potential to cause life-
threatening ventricular arrhythmias, especially in a subset of patients with ischaemic 
complications. In diabetes, mitochondrial KATP channel activation in cardiomyocytes by 
dioxide led to impaired APD adaptation, which promoted the occurrence of VT [85]. Future 
efforts therefore require an integrated approach by computation modelling, where effects of 
drugs on complex spatiotemporal properties of cardiac dynamics are tested to reduce the 
likelihood of life-threatening side effects. Animal models will be useful for studying 
arrhythmogenic mechanisms and provide a platform for assessing the efficacy of 
pharmacological therapy [86-91]. 
 
Figure legends 
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Figure 1. Both conduction and repolarization abnormalities promote arrhythmogenesis in 
diabetes. 
Figure 2. Cardiac and extra-cardiac factors responsible for promoting arrhythmogenesis in 
diabetes. 
 
Table 1 
Molecular target Mechanism of action References 
Gap junction inhibitors Increase refractory period 
Improve conduction 
[14, 83] 
Gap junction openers Increase conduction velocity, 
decrease heterogeneity in 
repolarization or refractoriness 
[82] 
Late sodium channel blockers Inhibit afterdepolarizations [81] 
Ryanodine receptor stabilizers Decrease heterogeneity in Ca
2+
 
transients; inhibit 
afterdepolarizations 
[84] 
Anti-fibrotic agents Reduce cardiac fibrosis [80] 
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